Genferon Light, spray 50000 meg+1 mg/dose 100 doses

The product contains recombinant human interferon alfa-2b, produced by Escherichia coli bacterial strain, into which human interferon alfa-2b gene was introduced by genetic engineering methods. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effect.

Antiviral effect is mediated by activation of a number of intracellular enzymes that inhibit virus replication. Immunomodulatory action is primarily manifested by strengthening the cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T-cells, NK-cells (natural killer cells), increased differentiation.

B-lymphocytes and their production of antibodies, activation of monocytic-macrophage system and phagocytosis, as well as increasing the expression of histocompatibility complex type I molecules, which increases the recognition of infected cells by the cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane provides their active participation in liquidation of pathological foci; besides, due to the influence of interferon the restoration of production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by the reactions of the immune system, strengthened under the influence of interferon.

Taurine helps normalize metabolic processes and tissue regeneration, has a membrane stabilizing and immunomodulatory action.

As a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to pathological processes. Taurine helps to maintain the biological activity of interferon, increasing the therapeutic effect of the drug.

Pharmacokinetics

In intranasal administration due to high concentration in the focus of infection a pronounced local antiviral and immunostimulatory effect is achieved.

The systemic absorption of the drug is insignificant – the low bioavailability of the drugs during intranasal administration is associated with the functioning of a special family of 25 proteins which are part of the nasal mucosa and which control the transport of all molecular and cellular objects passing through the mucosa.

At the same time, a certain amount of the drug enters the systemic bloodstream, due to which a systemic immunomodulatory effect is achieved.

Indications

Prevention and treatment of influenza and ARVI in adults and children over 14 years of age.

Pharmacological effect

The composition of the drug Genferon® light includes recombinant human interferon alpha-2b, produced by a strain of the bacterium Escherichia coli, into which the human interferon alpha-2b gene was introduced using genetic engineering methods. Interferon alpha-2b has antiviral, immunomodulatory, antiproliferative and antibacterial effects.

The antiviral effect is mediated by the activation of a number of intracellular enzymes that inhibit viral replication. The immunomodulatory effect is manifested, first of all, by enhancing cell-mediated reactions of the immune system, which increases the effectiveness of the immune response against viruses, intracellular parasites and cells that have undergone tumor transformation. This is achieved through the activation of CD8+ T killer cells, NK cells (natural killer cells), and increased differentiation.

B lymphocytes and their production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increased expression of molecules of the major histocompatibility complex type I, which increases the likelihood of recognition of infected cells by cells of the immune system. Activation under the influence of interferon of leukocytes contained in all layers of the mucous membrane ensures their active

participation in the elimination of pathological foci; in addition, due to the influence of interferon, restoration of the production of secretory immunoglobulin A is achieved. The antibacterial effect is mediated by reactions of the immune system, enhanced under the influence of interferon.

Taurine helps normalize metabolic processes and tissue regeneration, has membrane-stabilizing and immunomodulatory effects.

Being a strong antioxidant, taurine directly interacts with reactive oxygen species, the excessive accumulation of which contributes to the development of pathological processes. Taurine helps maintain the biological activity of interferon, enhancing the therapeutic effect of the drug.

Pharmacokinetics

When administered intranasally, due to the high concentration at the site of infection, a pronounced local antiviral and immunostimulating effect is achieved.

Systemic absorption of the drug is insignificant – the low bioavailability of drugs when administered intranasally is associated with the functioning of a special family of proteins of 25 proteins that are part of the nasal mucosa and control the transport of all molecular and cellular objects that penetrate the mucosa.

At the same time, a certain amount of the drug enters the systemic bloodstream, thereby achieving a systemic immunomodulatory effect.

Active ingredient

Interferon alpha-2b, Taurine

Composition

1 dose of the drug contains:

active ingredients: human recombinant interferon alpha-2b* 50,000 IU, taurine 1 mg.

excipients: disodium edetate dihydrate, glycerol, dextran 40000, polysorbate 80, sodium chloride, potassium chloride, sodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, peppermint oil, methyl parahydroxybenzoate, water for injection up to 0.1 ml.

* The composition of the substance “Recombinant human interferon alpha-2b (rhIFN-α2b), substance-solution” includes recombinant human interferon alpha-2b (rhIFN-α2b) and excipients: sodium chloride, sodium acetate trihydrate, glacial acetic acid, water for injection.

Contraindications

Hypersensitivity to interferon alfa-2b or other components of the drug.

Children’s age up to 14 years.

Side Effects

Allergic reactions and bloody discharge from the nose are possible.

As a rule, these reactions are mild and do not require additional drug therapy.

Interaction

Concomitant use is not recommended
intranasal vasoconstrictor drugs, as this promotes
additional drying of the nasal mucosa.

Overdose

No cases of overdose of the drug Genferon® Light have been reported.

Storage conditions

Store and transport in a dry place, protected from light, at a temperature of 2 to 8 °C. Keep out of the reach of children.

Shelf life

2 years.

Manufacturer

Pharmstandard-UfaVITA, Russia